Cite
HARVARD Citation
Allanore, Y. et al. (2020). A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis. Annals of the rheumatic diseases. 79 (12), pp. 1600-1607. [Online].